Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 3/20 | 0.34 |
| ▸ | DTYMK | P23919 | 1/20 | 0.30 |
| ▸ | GLS | O94925 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18107012 | 0.87 | GLS (0.33) | KRASGLS | |
| SCHEMBL18114793 | 0.83 | GLS (0.31) | KRASGLS | |
| SCHEMBL20018577 | 0.82 | GLS (0.32) | GLS | |
| SCHEMBL18114791 | 0.81 | DTYMK (0.35) | KRASDTYMKGLS | |
| SCHEMBL21638825 | 0.75 | NR1H2 (0.32) | GLS | |
| SCHEMBL20111128 | 0.75 | MAPT (0.33) | GLS | |
| SCHEMBL21638878 | 0.73 | DTYMK (0.39) | KRASDTYMK | |
| SCHEMBL18114790 | 0.71 | NR1H2 (0.33) | KRASDTYMKGLS | |
| SCHEMBL5186984 | 0.71 | BCDIN3D (0.35) | KRAS | |
| SCHEMBL20022741 | 0.70 | NAMPT (0.36) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277277-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2021-01-06 | — | — | EP | disclosed |
| EP-3277277-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2021-01-06 | — | — | EP | disclosed |
| CN-107438614-B | Heterocyclic compounds and their use in the prevention or treatment of bacterial infections | 拜欧蒂姆公司 | 2020-01-31 | — | — | CN | disclosed |
| US-20180118765-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-05-03 | — | — | US | disclosed |
| US-20180118765-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-05-03 | — | — | US | disclosed |
| EP-3277277-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016156597-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016156597-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118765-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | NQO1, PEPD, LCT | KRAS 651/4885DTYMK 1014/4885GLS 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.